Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna (MRNA) stock gains as company posts better than expected Q3 results driven by its updated COVID-19 vaccine. Read more ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three vaccines available in the U.S.

Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...

This marks the third year that vaccine manufacturers have updated their COVID-19 vaccine formulations to better ... As it has ...

Moderna (MRNA) got a boost in the third quarter from an earlier US approval of its updated COVID-19 vaccine, underpinning sales growth and helping drive a surprise net income result at the drugmaker.

On Aug. 22, the Food and Drug Administration approved and authorized ... This marks the third year that vaccine manufacturers have updated their COVID-19 vaccine formulations to better match ...